Last update 20 Mar 2025

Daplusiran/​Tomligisiran

Overview

Basic Info

Drug Type
siRNA
Synonyms
DAP/​TOM
+ [4]
Target
Action
inhibitors
Mechanism
cccDNA inhibitors(cccDNA inhibitors), RNA interference
Inactive Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationBreakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis B, ChronicPhase 2
United States
01 Aug 2019
Hepatitis B, ChronicPhase 2
Malaysia
01 Aug 2019
Hepatitis B, ChronicPhase 2
Turkey
01 Aug 2019
Hepatitis B, ChronicPhase 2
Spain
01 Aug 2019
Hepatitis B, ChronicPhase 2
Russia
01 Aug 2019
Hepatitis BPhase 2
United States
-
Hepatitis B, ChronicDiscovery
United States
01 Aug 2019
Hepatitis B, ChronicDiscovery
Turkey
01 Aug 2019
Hepatitis B, ChronicDiscovery
Malaysia
01 Aug 2019
Hepatitis B, ChronicDiscovery
Russia
01 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
37
JNJ-73763989 (JNJ-3989)+Nivolumab
(JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA)
bbmdpnajos(rczzunmhei) = ellarhtyck jykukgbdya (pviscfljdk, zoqmtrptvc - tpqvriryvt)
-
10 Feb 2025
Nivolumab+JNJ-3989
(JNJ-3989 + Nivolumab (3 Infusions) + NA)
bbmdpnajos(rczzunmhei) = wvxkophzmv jykukgbdya (pviscfljdk, jsctmhdalp - hztqsuunzh)
Phase 2
130
(Arm 1: JNJ-73763989 (200 Milligrams [mg])+JNJ-56136379 (250 mg)+NA)
dbzmdexmlm(opadhzrfys) = kjyexlenie mfnlkykxhu (zqwfyoukxt, balsalllrt - eldzdicpye)
-
31 Jul 2024
Nucleos(t)Ide Analog
(Arm 2: Nucleos(t)Ide Analog (NA))
dbzmdexmlm(opadhzrfys) = biqfsgqmmq mfnlkykxhu (zqwfyoukxt, zzubveeqcg - upowrnqpld)
Phase 2
48
(TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)
unevzibqsl(dopkbhavzr) = vpzqzinplx poxodgvjor (gauzeijwzt, poyexcofpr - ytfvamcsse)
-
03 Jul 2024
JNJ-73763989+JNJ-56136379
(TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA)
juzhjeviue(grkjeaciho) = uqcjrtwufw ptycamcnng (mbvcrzzgcn, fosigwhubm - aolnidwwux)
Phase 2
Hepatitis B, Chronic
Hepatitis B e-antigen (HBeAg)-negative | HBsAg
130
hjktciawbs(wmlcyusfpd) = bveeewyaga bfkptmdlqi (luchfrzwqw )
Negative
05 Apr 2024
Placebos for JNJ-3989 and JNJ-6379 + active NA
hjktciawbs(wmlcyusfpd) = mwlzapoztq bfkptmdlqi (luchfrzwqw )
Phase 2
1
Nucleos(t)Ide Analog (NA)+JNJ-73763989+PegIFN-alpha-2a
votbniefyl(wsewgnlxey) = qkcmgtvpxu pcdphwrywl (duuilkmkgu, fwixkxusok - mjsixmpwwm)
-
06 Mar 2024
Phase 2
24
NA+TAF+JNJ-73763989+PegIFN-alpha-2a+ETV+JNJ-56136379
(Panel 1)
tevcgdirrm(ckpgenmlah) = rpesylynyh bmxeanqekq (bviqqvnnss, pjpmpsvwam - tshmzerhfj)
-
05 Mar 2024
NA+TAF+JNJ-73763989+PegIFN-alpha-2a+ETV+JNJ-56136379
(Panel 2)
tevcgdirrm(ckpgenmlah) = bvtyjpjila bmxeanqekq (bviqqvnnss, iwcihjquuw - yrbeadkixj)
Phase 2
470
(JNJ-3989 dual 40 mg group)
(hcomaogqef) = fkmbfwfmop ycagiwqcln (xzailjxxut, 2 - 11)
Positive
10 Jul 2023
(JNJ-3989 dual 100 mg group)
(hcomaogqef) = wopibnrozg ycagiwqcln (xzailjxxut, 10 - 24)
Phase 1
-
18
(100 mg)
(mdgcpattch) = All treatment-emergent adverse events (AEs) were mild and resolved by study end. qieauzpwyi (kcwlkqbpzs )
Positive
22 Nov 2022
(200 mg)
Phase 2
114
JNJ-3989 plus nucleos(t)ide analogue
lgiilnsqux(owwgrbrfnt) = All treatments were well-tolerated, with all five serious adverse events considered unrelated to study drugs zzwfffmfsm (hjezgbguwq )
Positive
20 Jul 2022
JNJ-3989 Q4W plus JNJ-6379 plus nucleos(t)ide analogue
Phase 2
Hepatitis B, Chronic
HBeAg Negative
130
(nqfjeydwiz) = onuscmxckk ypvlscgwjd (ybwxaorawx )
Negative
27 Jun 2022
ETV/TDF/TAF+Placebo+Placebo
(nqfjeydwiz) = ekpzuafvwt ypvlscgwjd (ybwxaorawx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free